Published in Cardiovascular Week, January 12th, 2004
According to published research from the United States, "There remains no treatment for chronic allograft rejection mainly manifested by progressive arteriosclerosis."
W. Li and coauthors at the University of Pittsburgh "investigated the effect of Allotrap peptide RDP58 therapy on arteriosclerosis in an aortic allotransplant model."
"RDP58 was administered intraperitoneally at 0.1, 0.5, or 2.5 mg/kg, every other day after transplantation," they explained. Test results showed that "RDP58 therapy markedly inhibited vascular intimal thickening, media...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.